NCT07401472

Study of BW-50218 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Detailed description

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants

Conditions

• Healthy Participants Study

Interventions

Type	Name	Description
DRUG	BW-50218 Injection	Solution for injection
DRUG	Saline (0.9% NaCl)	Solution for injection

Timeline

• Start date: 2026-03-12
• Primary completion: 2027-06-30
• Completion: 2027-06-30
• First posted: 2026-02-10
• Last updated: 2026-04-13

Locations

2 sites across 1 country: Australia